tisotumab vedotin   Click here for help

GtoPdb Ligand ID: 11719

Synonyms: HuMax-TF-ADC | TF-011-MMAE | tisotumab vedotin-tftv | Tivdak®
Approved drug
tisotumab vedotin is an approved drug (FDA (2021))
Compound class: Antibody
Comment: Tisotumab vedotin is an antibody-drug conjugate (ADC) of an anti-factor 3 monoclonal antibody that is conjugated to the antineoplastic agent monomethyl auristatin E (MMAE; PubChem CID 11542188) [1]. Tisotumab vedotin causes adverse events that are associated with disrupted coagulation [4].
No information available.
Summary of Clinical Use Click here for help
Tisotumab vedotin was developed to treat solid tumours that aberrantly express F3. High expression of F3 in cervical cancer is associated with poor prognosis.
The first FDA approval of tisotumab vedotin was as a treatment for previously treated recurrent or metastatic cervical cancer, in September 2021 [5]. Click here to link to ClinicalTrials.gov's full list of tisotumab vedotin studies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02001623 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2 Interventional Seagen Inc. 3
NCT03438396 A Trial of Tisotumab Vedotin in Cervical Cancer Phase 2 Interventional Seagen Inc. 2